Fingerprint
Dive into the research topics of 'Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma
C. M.M. Prado, T. Bekaii-Saab, L. A. Doyle, S. Shrestha, S. Ghosh, V. E. Baracos, M. B. Sawyer
Research output: Contribution to journal › Article › peer-review
79
Scopus
citations